Swiss biotech company TargImmune is announcing a new international research collaboration with Australia’s oldest medical research institute, the Walter and Eliza Hall Institute, to progress the
In November 2017, Race CEO Peter Molloy spoke to investors in London at the Biotech & Money conference.
A Perth family tells the story of their son’s battle with Acute Myeloid Leukaemia. When Kai got sick, they searched the world for answers.
Race Oncology Limited (RAC) is pleased to announce it has produced its first good manufacturing practice (GMP) batch of cancer drug Bisantrene.
Betadine is the largest selling sore throat treatment in Australia.
Race Oncology Limited (ASX: RAC) announced today that it has executed a Letter of Intent with TargImmune Therapeutics AG (Basel, Switzerland) to enter into a joint venture between the two companies.